UBS Maintains Neutral on Corteva, Lowers Price Target to $86

Benzinga Newsdesk www.benzinga.com Negative 75.1%

Neg 75.1% Neu 0% Pos 0%

UBS analyst Joshua Spector maintains Corteva (NYSE:CTVA) with a Neutral and lowers the price target from $90 to $86.

Comments

No comments yet. Be the first!